Contact Us

Home About Sudair Company Overview

Company Overview

Welcome to Sudair Pharma

Sudair Pharma is a Saudi pharmaceutical manufacturer committed to improving lives through high-quality medicines, advanced manufacturing, and continuous innovation, while supporting the localization of pharmaceutical production across the Kingdom and the region.
Patients served
0 M+
Registered products
0 +
Therapeutic areas
0 +
International markets
0 +

The Story of Sudair Pharma

Our Story

Driven by a vision to strengthen pharmaceutical manufacturing in Saudi Arabia, Sudair Pharma is dedicated to localizing the production of advanced medicines while supporting regional healthcare needs through innovation, scientific excellence, and world-class manufacturing.

Through strategic international partnerships and continuous investment in advanced technologies, the company has expanded its manufacturing capabilities across a broad range of therapeutic areas, delivering high-quality pharmaceutical products that support healthcare systems across Saudi Arabia and international markets.

This is a title

Our Story

The Story of Sudair Pharma

Driven by a vision to strengthen pharmaceutical manufacturing in Saudi Arabia, Sudair Pharma is dedicated to localizing the production of advanced medicines while supporting regional healthcare needs through innovation, scientific excellence, and world-class manufacturing.

Through strategic international partnerships and continuous investment in advanced technologies, the company has expanded its manufacturing capabilities across a broad range of therapeutic areas, delivering high-quality pharmaceutical products that support healthcare systems across Saudi Arabia and international markets.

Our Journey

From our establishment in 2013 to becoming one of Saudi Arabia’s leading pharmaceutical manufacturers, every milestone reflects our commitment to innovation, localization, and improving patient lives.

  1. Pharmaceutical facility interior

    2013

    The company is founded

    • Sudair Pharma Company was established in February 2013.
  2. Manufacturing plant exterior

    2015

    Breaking ground in oncology

    • Construction commenced on our first dedicated oncology manufacturing facility.
  3. Pharmaceutical production line

    2017

    Technology transfer begins

    • Signed our first technology and knowledge transfer agreement for oncology medicines.
    • Completed construction of our first dedicated oncology manufacturing facility.
  4. Pharmaceutical vials

    2018

    First products reach patients

    • Registered our first portfolio of 11 products with the Saudi Food and Drug Authority (SFDA).
    • Successfully launched our first oncology product.
  5. Medical team in discussion

    2019

    Beyond the Kingdom

    • Expanded into the Bahraini market with our oncology portfolio.
    • Registered 3 additional products, bringing the total portfolio to 14 products.
  6. Analytical instrumentation

    2020

    Portfolio triples

    • Registered 31 new products, increasing the portfolio to 45 products.
    • Expanded into the United Arab Emirates.
  7. Quality inspection of pharmaceutical products

    2021

    New therapeutic areas

    • Registered 16 additional products, reaching 61 registered products.
    • Expanded into anticoagulants, anti-infectives, multiple sclerosis therapies, and epilepsy treatments.
    • Awarded the Good Manufacturing Practice (GMP) Certificate by the Ministry of Health of Libya.
    • Successfully localized our first oncology product.
  8. Pharmaceutical tablets

    2022

    Four therapeutic areas

    • Registered 5 additional products.
    • Portfolio reached 67 products across oncology, respiratory, neurology, and anti-infective therapeutic areas.
  9. Production hall interior

    2023

    Localization at scale

    • Registered 14 new products, bringing the portfolio to 81 registered products.
    • First products registered in Lebanon and Libya.
    • Localized the manufacturing of more than 10 pharmaceutical products, strengthening technology transfer and supply chain resilience.
  10. Colleagues collaborating

    2024

    A landmark year

    • Signed our first Purchase Commitment Agreement with NUPCO.
    • Registered 20 additional products, increasing the portfolio to 95 products.
    • Successfully localized the first generic medicine for the prevention and treatment of blood clots.
    • Our medicines contributed to the treatment of more than 750,000 patients.
    • Launched the major expansion project of the Sudair Manufacturing Complex.
    • Signed a strategic partnership with the Local Content and Government Procurement Authority (LCGPA).
    • Launched the Gharas Program.
    • Introduced new products across oncology, diabetes, and respiratory therapeutic areas.
  11. Precision pipetting in the laboratory

    2025

    Into insulin

    • Construction commenced on our dedicated insulin manufacturing facility for end-to-end insulin production.
    • Localized 13 additional pharmaceutical products, bringing the total number of locally manufactured products to 35.
    • Registered 13 additional products, increasing the total registered portfolio to 108 products.
    • Scroll to explore

Built in Sudair, supplying the world

A decade of investment in local pharmaceutical manufacturing capability.